Entera Bio Ltd (ENTX) News
Filter ENTX News Items
ENTX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest ENTX News From Around the Web
Below are the latest news stories about ENTERA BIO LTD that investors may wish to consider to help them evaluate ENTX as an investment opportunity.
Entera Bio Ltd. (ENTX) Reports Q3 Loss, Tops Revenue EstimatesEntera Bio (ENTX) delivered earnings and revenue surprises of -60% and 5%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock? |
Entera Bio Reports Q3 2024 Financial Results and Provides Business UpdatesJERUSALEM, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of oral peptides and small therapeutic proteins, today reported financial results and key business updates for the quarter ended September 30, 2024. “The third quarter of 2024 drew consistent attention to our pivotal-staged clinical asset, EB613, the first oral PTH(1-34) tablet treatment dedicated to post-menopausal women with high risk osteoporosis. Entera’s propr |
Are Medical Stocks Lagging Argenx (ARGX) This Year?Here is how argenex SE (ARGX) and Entera Bio Ltd. (ENTX) have performed compared to their sector so far this year. |
ENTX & OPK Stock May Gain Following Positive PK/PD Research DataEntera and OPKO Health announce positive PK/PD results from their ongoing collaborative research focused on developing the first oral dual agonist GLP-1/glucagon peptide. |
Entera Bio and OPKO Health Provide Update on PK/PD Results of Oral Oxyntomodulin (GLP-1/Glucagon) Peptide Tablet Candidate for Obesity and Metabolic DisordersJERUSALEM and MIAMI, Sept. 25, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX) (Entera), a leader in the development of orally delivered peptides, and OPKO Health, Inc. (NASDAQ: OPK) (OPKO) announced today topline pharmacokinetic/pharmacodynamic (PK/PD) results from their ongoing collaborative research combining a proprietary long-acting oxyntomodulin (OXM) analog developed by OPKO and Entera’s proprietary N-Tab™ technology. The program is focused on developing the first oral dual agonis |
Is Entera Bio (ENTX) Stock Outpacing Its Medical Peers This Year?Here is how Entera Bio Ltd. (ENTX) and argenex SE (ARGX) have performed compared to their sector so far this year. |
Is Entera Bio (ENTX) Outperforming Other Medical Stocks This Year?Here is how Entera Bio Ltd. (ENTX) and Akebia Therapeutics (AKBA) have performed compared to their sector so far this year. |
We're Keeping An Eye On Entera Bio's (NASDAQ:ENTX) Cash Burn RateWe can readily understand why investors are attracted to unprofitable companies. Indeed, Entera Bio ( NASDAQ:ENTX... |
Entera Bio to Participate in Upcoming Investor and Scientific ConferencesJERUSALEM, Aug. 20, 2024 (GLOBE NEWSWIRE) -- Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and small therapeutic proteins, today announced that management will be participating in the following investor and scientific conferences: H.C. Wainwright 26th Annual Global Investment Conference (Presentation and 1x1) Date and Time: September 9, 2024 at 7am ETLocation: Virtual, September 9-11, 2024 American Society for Bone and Minera |
All You Need to Know About Entera Bio (ENTX) Rating Upgrade to BuyEntera Bio (ENTX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |